Upfront triple oral combination therapy including selexipag in a high-risk patient with idiopathic pulmonary arterial hypertension: a case report

BACKGROUND : Selexipag is an oral selective prostacyclin IP receptor agonist approved in patients with low- and intermediate-risk pulmonary hypertension (PH); evidence in patients at high risk is lacking. CASE SUMMARY : A 42-year-old woman with worsening dyspnoea (World Health Organization functiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Serena, Pietrangelo, Carla, Pierdomenico, Sante Donato, Giuliani, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649462/
https://www.ncbi.nlm.nih.gov/pubmed/33204960
http://dx.doi.org/10.1093/ehjcr/ytaa190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649462/
https://www.ncbi.nlm.nih.gov/pubmed/33204960
http://dx.doi.org/10.1093/ehjcr/ytaa190

Ejemplares similares